Eli Lilly, the renowned global pharmaceutical company, has announced the launch of Copellor® (Ixekizumab) in India. Copellor® is designed to provide relief to adults with moderate-to-severe plaque psoriasis and psoriatic arthritis. According to recent studies, psoriasis is a chronic autoimmune disease that affects 125 million people worldwide, with a prevalence of 0.44-2.8% in India alone. Psoriatic arthritis, a type of inflammatory arthritis that affects some people with psoriasis, is also on the rise in India.
A humanized IgG4 monoclonal antibody, Copellor® specifically targets the IL-17A protein responsible for inflammation in psoriasis. The Drug Controller General of India (DCGI) has approved the drug, which is available in a single-dose prefilled autoinjector of 80mg/ml strength. The launch of Copellor® in India reinforces Eli Lilly’s commitment to improving patient outcomes and quality of life by providing innovative treatments.
Eli Lilly’s introduction of Copellor® in India comes at a crucial time when the prevalence of psoriasis and psoriatic arthritis is increasing. In India, a recent study showed that psoriasis prevalence is highest in the northern region of the country and among urban populations. Copellor®’s launch offers healthcare providers an additional treatment option to alleviate the impact of these conditions. It is, however, recommended that Copellor® be used only on the advice of a dermatologist or rheumatologist and under medical supervision.
In conclusion, Eli Lilly’s Copellor® launch in India is a significant step towards improving the quality of life for patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. With the introduction of Copellor® to the Indian market, healthcare providers can now offer patients an alternative treatment option to alleviate the impact of psoriasis and psoriatic arthritis. As the prevalence of these conditions continues to rise in India and worldwide, Eli Lilly’s commitment to providing effective treatment options and improving patient outcomes is more important than ever.
